However, the proportion of monoclonal gammopathy in the patients with C3G far exceeded the expected rate in the general population according to the latest MGRS consensus, although the monoclonal Ig acting as a C3 nephritic factor or anti-factor-H antibody renal disease can be demonstrated in only about 30% of patients affected by C3 glomerulopathy, it should still be considered an MGRS-associated disorder [3]. This evidence concerns the gene C3 and kidney disorder.